Also, treatment of T2DM patients with MitoQ decreased mitochondrial ROS production, as well as the level of NFκB-p65 and TNFα, supporting the idea that MitoQ shows anti-inflammatory and antioxidant properties [59]. Here, NFKB1 is linked to type 2 diabetes mellitus.